Kanaoka Y, Umesaki N, Kawabata M, Tsuda H, Sugawa T
Department of Obstetrics and Gynecology, Osaka City University Medical School.
Nihon Gan Chiryo Gakkai Shi. 1990 May 20;25(5):1027-31.
Recombinant interleukin-2 (rIL-2) was administered intraperitoneally for 15 days, 2 days after intraperitoneal administration of Streptococcal preparation OK-432 to a patient of peritonitis carcinomatosa occurred eight months after second look operation, in which residual tumor could not be removed completely. The patient had been maintained by hemodialysis three times a week for over ten years. Combination chemotherapy using CDDP and Ifosfamide, or CDDP and THP-Adriamycin had not been effective to control rapidly increasing ascites. Negative cytological exam, was achieved on day 7 and ascites disappeared by day 15. No severe side effects including fluid retention were observed. Fever up was controllable by Indomethacin. Flow cytometric analysis revealed dominant (73%) CD4+, CD29+ helper inducer subset, while CD4+, CD45RA+ was 6%, in the lymphocytes in ascites on day 8. It was suggested that intraperitoneal administration of rIL-2 after OK-432 was safe and effective for peritonitis carcinomatosa with chronic renal failure.
在二次探查手术后八个月发生癌性腹膜炎的患者中，腹腔内残留肿瘤无法完全切除，在腹腔注射链球菌制剂OK-432两天后，重组白细胞介素-2（rIL-2）腹腔注射15天。该患者每周进行三次血液透析维持治疗已超过十年。使用顺铂和异环磷酰胺或顺铂和吡柔比星的联合化疗未能有效控制迅速增加的腹水。第7天腹水细胞学检查呈阴性，第15天腹水消失。未观察到包括液体潴留在内的严重副作用。吲哚美辛可控制体温升高。流式细胞术分析显示，第8天腹水中淋巴细胞中占主导地位（73%）的是CD4 +、CD29 +辅助诱导亚群，而CD4 +、CD45RA +占6%。提示OK-432后腹腔注射rIL-2对伴有慢性肾衰竭的癌性腹膜炎安全有效。
